急性冠状动脉综合征患者经皮冠状动脉支架置入术后应用替格瑞洛临床疗效.docVIP

急性冠状动脉综合征患者经皮冠状动脉支架置入术后应用替格瑞洛临床疗效 　　【摘要】 目的：探?急性冠状动脉综合征（ACS）患者经皮冠状动脉支架置入（PCI）术后应用替格瑞洛的临床疗效。方法：选取笔者所在医院2014年1月-2015年4月收治的126例ACS并行PCI患者，采用奇偶分组法分为对照组和观察组。对照组患者采用氯吡格雷治疗，观察组患者采用替格瑞洛治疗。对比两组患者治疗前和治疗后3、7、14 d的血小板抑制率；并对所有患者随访1年，对比两组患者出血事件、不良事件和不良反应的发生情况。结果：治疗后3、7、14 d，观察组患者的血小板抑制率分别为（58.8±6.3）%、（83.9±6.7）%、（85.2±7.3）%，对照组分别为（35.8±5.9）%、（58.1±6.2）%、（59.7±6.8）%，均明显高于治疗前，且观察组患者治疗后各时期的血小板抑制率均显著优于对照组，差异均有统计学意义（P0.05）；对照组患者再发心绞痛的发生率9.52%，观察组无再发心绞痛患者，但观察组呼吸困难的发生率为6.35%，而对照组患者无呼吸困难发生，组间比较差异均有统计学意义（P0.05）。结论：替格瑞洛可显著提高ACS患者的血小板抑制率，且可降低PCI术后患者不良事件的发生率，但发生呼吸困难的概率较高，因此临床使用需谨慎考虑，以减少不良事件的发生 【关键词】 急性冠状动脉综合征； 经皮冠状动脉支架置入； 替格瑞洛 doi：10.14033/j.cnki.cfmr.2016.36.002 文献标识码 A 文章编号 1674-6805（2016）36-0003-02 Clinical Effect of Postoperative Application of Ticagrelor after Percutaneous Coronary Stent Implantation in Patients with Acute Coronary Syndrome/LI Ai-gui.//Chinese and Foreign Medical Research，2016，14（36）：3-4 【Abstract】 Objective：To investigate the clinical effect of Ticagrelor in patients with acute coronary syndrome（ACS） after percutaneous coronary stent implantation（PCI）.Method：126 cases of ACS patients in our hospital from January 2014 to April 2015 were selected and divided into the control group and the observation group by using the odd even grouping method.The control group was treated with Clopidogrel，the observation group was treated with Ticagrelor.The platelet inhibition rate of before treatment and 3 d，7 d and 14 d after treatment were compared between the two groups.All patients were followed up for 1 year.The incidence of bleeding events，adverse events and adverse reactions were compared between the two groups.Result：3 d，7 d and 14 d after treatment，the platelet inhibition rates of the observation group were （58.8±6.3）%，（83.9±6.7）%，（85.2±7.3）%，the control group were （35.8±5.9）%，（58.1±6.2）%，（59.7±6.8）%，which were significantly better than before treatment，and the platelet inhibition rates of the patients in the observation group each period after treatment were signi